THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.17] ID: TIP-MED-000061

Linagliptin

Active Ingredient / Scientific Identity: Linagliptin • Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitor — Biliary/Non-Renally Cleared (Schedule H)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Linagliptin ([4.17] | ID: TIP-MED-000061) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/4-17-linagliptin/
Generic / Entity NameLinagliptin ([4.17])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassDipeptidyl Peptidase-4 (DPP-4) Inhibitor — Biliary/Non-Renally Cleared (Schedule H)
Available Dosage FormsFilm-Coated Tablets: 5 mg; FDCs with Metformin (2.5/500 mg, 2.5/1000 mg) or Empagliflozin (Glyxambi 10/5 mg, 2
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: >85% excreted unchanged via bile/gut — ZERO dose adjustment required in Stage G1–G5 CKD or haemodialysis! Hepatic: No
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Linagliptin (TIP-MED-000061, Reference Code [4.17]) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor — Biliary/Non-Renally Cleared (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.17], p. 53): Trajenta (Boehringer), Ondero (Lupin), Linares (Sun), Linaglip (Zydus) — Strengths & Dosage Forms: Film-Coated Tablets: 5 mg; FDCs with Metformin (2.5/500 mg, 2.5/1000 mg) or Empagliflozin (Glyxambi 10/5 mg, 25/5 mg)
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.17], p. 53): Trajenta (Boehringer), Ondero (Lupin), Linares (Sun), Linaglip (Zydus) — Strengths & Dosage Forms: Film-Coated Tablets: 5 mg; FDCs with Metformin (2.5/500 mg, 2.5/1000 mg) or Empagliflozin (Glyxambi 10/5 mg, 25/5 mg)
Dosage Forms & Available Strengths:
Film-Coated Tablets: 5 mg; FDCs with Metformin (2.5/500 mg, 2.5/1000 mg) or Empagliflozin (Glyxambi 10/5 mg, 25/5 mg)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Dipeptidyl Peptidase-4 (DPP-4) Inhibitor — Biliary/Non-Renally Cleared (Schedule H) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Dipeptidyl Peptidase-4 (DPP-4) Inhibitor — Biliary/Non-Renally Cleared (Schedule H) for Type 2 Diabetes Mellitus across all stages of renal impairment (including CKD Stage 4–5 and dialysis where Metformin and other gliptins require reduction or cessation).

4. Therapeutic Indications & Evidence-Supported Uses

  • Type 2 Diabetes Mellitus across all stages of renal impairment (including CKD Stage 4–5 and dialysis where Metformin and other gliptins require reduction or cessation)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: 5 mg PO Once Daily across all levels of renal and hepatic function (no dose titration required)

Administration & Meal Timing: May be taken with or without food at any consistent time of day | Morning (Once Daily)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: >85% excreted unchanged via bile/gut — ZERO dose adjustment required in Stage G1–G5 CKD or haemodialysis! Hepatic: No adjustment required in Child–Pugh A/B/C
Elimination & Renal Adjustment:
Renal: >85% excreted unchanged via bile/gut — ZERO dose adjustment required in Stage G1–G5 CKD or haemodialysis! Hepatic: No adjustment required in Child–Pugh A/B/C
Hepatic Impairment Considerations:
Renal: >85% excreted unchanged via bile/gut — ZERO dose adjustment required in Stage G1–G5 CKD or haemodialysis! Hepatic: No adjustment required in Child–Pugh A/B/C

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in Type 1 DM, diabetic ketoacidosis (DKA), and history of gliptin-induced acute pancreatitis or bullous pemphigoid

Key Clinical Precautions: Renal: >85% excreted unchanged via bile/gut — ZERO dose adjustment required in Stage G1–G5 CKD or haemodialysis! Hepatic: No adjustment required in Child–Pugh A/B/C

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nasopharyngitis, mild headache (weight-neutral; minimal intrinsic hypoglycaemia unless combined with a Sulfonylurea or Insulin)
  • Acute pancreatitis (severe persistent epigastric pain radiating to the back), bullous pemphigoid (blistering skin rash), severe disabling arthralgia
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Rifampicin (strong P-gp/CYP3A4 inducer) reduces Linagliptin efficacy; when added to Glimepiride/Gliclazide or Insulin, reduce secretagogue/insulin dose by 20–25% to prevent hypoglycaemia

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Preferred gliptin in kidney disease because the 5 mg once-daily dose never needs adjustment; stop immediately and seek medical care if severe abdominal pain or skin blisters occur
  • Meal & Clock Timing Instruction: May be taken with or without food at any consistent time of day (Morning (Once Daily))
  • Missed Dose Protocol: Take same day if remembered; skip if next day; never double dose
  • Geriatric Dispensing Pearl: First-choice oral incretin agent in frail older adults and elderly CKD patients (no hypoglycaemia when used without SU/Insulin)

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Film-Coated Tablets: 5 mg; FDCs with Metformin (2.5/500 mg, 2.5/1000 mg) or Empagliflozin (Glyxambi 10/5 mg, 25/5 mg)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.17] (p. 53)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/4-17-linagliptin/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.